Rockwell Medical, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 12, 2026, reporting a net loss of $2,324 thousand for the third quarter and $5,101 thousand for the nine months ended September 30, 2026.
Key Highlights
- Q3 net sales: $19,122 thousand for the three months ended September 30, 2026, up from $15,927 thousand in the same period of 2025, according to the filing.
- Q3 net loss: $(2,324) thousand, or $(0.59) per basic and diluted share, compared to $(1,753) thousand, or $(0.49) per share, in Q3 2025.
- Nine-month net loss: $(5,101) thousand for the nine months ended September 30, 2026, versus $(4,760) thousand for the same period in 2025.
- Transaction-related expenses: $847 thousand recorded in Q3 2026, with no comparable amount in Q3 2025, as disclosed in the filing.
- Total assets: $57,084 thousand as of September 30, 2026, essentially flat compared to $57,145 thousand at December 31, 2025.
- Accumulated deficit: $(408,093) thousand as of September 30, 2026, up from $(402,992) thousand at December 31, 2025.
- Shares outstanding: 3,971,968 shares of common stock issued and outstanding as of September 30, 2026, reflecting a reverse stock split adjustment during Q3 2026.
Rockwell Medical's Third-Quarter 2026 Financial Results and Balance Sheet Position
According to the Form 10-Q filed with the SEC, Rockwell Medical, Inc. (NASDAQ:RMTI) reported net sales of $19,122 thousand for the three months ended September 30, 2026, an increase from $15,927 thousand in the corresponding quarter of 2025. Cost of sales rose to $16,011 thousand from $13,655 thousand, producing gross profit of $3,111 thousand in Q3 2026 versus $2,272 thousand in Q3 2025. The company reported an operating loss of $(2,221) thousand for the quarter, widening from $(1,584) thousand in Q3 2025. The filing identified $847 thousand in transaction-related expenses during Q3 2026, with no such expenses recorded in the prior-year quarter.
For the nine months ended September 30, 2026, the filing disclosed net sales of $54,238 thousand, up from $50,912 thousand in the same period of 2025, while the nine-month operating loss totaled $(4,762) thousand compared to $(4,293) thousand in 2025. General and administrative expenses for the nine months were $11,296 thousand versus $10,296 thousand in the prior-year period. Interest expense for the nine months was $(845) thousand, compared to $(838) thousand in 2025.
As of September 30, 2026, the company reported total stockholders' equity of $33,135 thousand, down from $36,981 thousand at December 31, 2025. Cash and cash equivalents stood at $10,631 thousand, while term loans (current and long-term, net of issuance costs) totaled $9,050 thousand. The filing also noted that cash paid in lieu of fractional shares in a reverse stock split reduced common shares outstanding by 61 shares during Q3 2026. Preferred stock remained at 15,000 shares issued and outstanding, with 2,000,000 shares authorized, as of September 30, 2026.
What Was Disclosed
Rockwell Medical disclosed its unaudited condensed consolidated financial statements for Q3 and the nine months ended September 30, 2026, including an operating loss, widening accumulated deficit, transaction-related expenses of $847 thousand, and a reverse stock split that occurred during the quarter.




Please wait processing your request...